NCT07685808ClinicalTrials.gov
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity
باختصار
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…
المرحلة 2مطلوب 360 مشاركاً22 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07685808فتح هذا السجل في ClinicalTrials.govتمت المزامنة أول أمس
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 360 participants (target), run at 22 sites.
How this score is built
- Enrolment25/40
360 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration6/10
Planned over about 18 months
- Sponsor scale9/10
Regeneron Pharmaceuticals has led 250 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
الحالات
- Overweight or Obesity
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 2 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 360 مشاركاً |
الجهة الراعية والمتعاونون
- Regeneron Pharmaceuticals الجهة الراعية
الأذرع والتدخلات
- Olatorepatide arm 1EXPERIMENTAL
- Olatorepatide arm 2EXPERIMENTAL
- Olatorepatide arm 3EXPERIMENTAL
- Olatorepatide arm 4EXPERIMENTAL
- Olatorepatide arm 5EXPERIMENTAL
- Matching Placebo arm 6ACTIVE_COMPARATOR
التدخلات
- دواء Olatorepatide
Administered per the protocol
- دواء Placebo
Administered per the protocol
مقاييس النتائج
مقياس النتيجة الأولي
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
الإطار الزمني Up to approximately 60 weeks
مقياس النتيجة الأولي
Severity of TEAEs
الإطار الزمني Up to approximately 60 weeks
مقياس النتيجة الأولي
Percent change in body weight
الإطار الزمني From baseline to week 52
مقياس النتيجة الثانوي
Olatorepatide concentrations
الإطار الزمني Up to approximately 60 weeks
مقياس النتيجة الثانوي
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
الإطار الزمني Up to approximately 52 weeks
مقياس النتيجة الثانوي
Magnitude of ADA to olatorepatide
الإطار الزمني Up to approximately 52 weeks
التواريخ
| تاريخ البدء | 28 يوليو 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 21 يناير 2028 (تقديري) |
| الإتمام | 21 يناير 2028 (تقديري) |
| أول نشر | 6 يوليو 2026 (فعلي) |
| آخر تحديث | 18 نوفمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | نوفمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
22 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Flourish Research, Ravenswood Rheumatology | Chicago | Illinois | قيد التجنيد |
| Charter Research LLC - Chicago | Chicago | Illinois | قيد التجنيد |
| Alliance for Multispecialty Research (AMR) Clinical Miami | Doral | Florida | قيد التجنيد |
| AMR Clinical - Fort Myers | Fort Myers | Florida | قيد التجنيد |
| Tribe Clinical Research | Greenville | South Carolina | قيد التجنيد |
| AGA Clinical Trials | Hialeah | Florida | قيد التجنيد |
| Flourish Research, Nature Coast Clinical Research | Inverness | Florida | قيد التجنيد |
| Flourish Research, Jacksonville Center for Clinical Research | Jacksonville | Florida | قيد التجنيد |
| AMR Clinical - Lexington | Lexington | Kentucky | قيد التجنيد |
| K2 Medical Research Maitland LLC, Main Office | Maitland | Florida | قيد التجنيد |
| AMR Clinical - Mobile | Mobile | Alabama | قيد التجنيد |
| NYC Research Inc | New York | New York | قيد التجنيد |
| AMR Clinical - Chicago Oak Brook | Oak Brook | Illinois | قيد التجنيد |
| Velocity Clinical Research - Omaha | Omaha | Nebraska | قيد التجنيد |
| Rochester Clinical Research | Rochester | New York | قيد التجنيد |
| Flourish Research, Legacy Oaks Tower | San Antonio | Texas | قيد التجنيد |
| The IMA Group, IMA Clinical Research St. Petersburg | St. Petersburg | Florida | قيد التجنيد |
| Charter Research LLC - The Villages | The Villages | Florida | قيد التجنيد |
| Diablo Clinical Research - Flourish Research | Walnut Creek | California | قيد التجنيد |
| Chase Medical Research | Waterbury | Connecticut | قيد التجنيد |
| AMR Clinical Wichita | Wichita | Kansas | قيد التجنيد |
| Clinical Site Partners, LLC DBA Flourish Research | Winter Park | Florida | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 18 نوفمبر 2026
أُضيف موقع
1 site added (22 total)
2122
- 13 أكتوبر 2026
أُضيف موقع
3 sites added (21 total)
1821
- 29 سبتمبر 2026
أُضيف موقع
13 sites added (18 total)
518
- 20 أغسطس 2026
تغيّرت الحالة
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 20 أغسطس 2026
فُتح التجنيد
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 20 أغسطس 2026
أُضيف موقع
5 sites added (5 total)
05